Physician profile
Allyssa E Beall
NPI 1285295865
$7,199.30
in general payments reported to CMS, 2019-2025
29 companies · $2,076 in 2025
The $2,076 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $283 · 2022: $890 · 2023: $2,495 · 2024: $1,455 · 2025: $2,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,026.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,888.52 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,034.62 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $586.01 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $459.90 | 2021-2025 | Trintellix |
| Abbvie INC. | $439.47 | 2022-2025 | |
| Lilly USA, LLC | $355.74 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Glaxosmithkline, LLC. | $281.79 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $237.38 | 2022-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.18 | 2021-2024 | |
| Astellas Pharma US INC | $207.95 | 2021-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $189.35 | 2022-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $179.27 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $154.65 | 2023-2024 | Caplyta |
| Phathom Pharmaceuticals, INC. | $123.17 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $117.55 | 2021-2023 | Verquvo, Belsomra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $115.24 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.97 | 2022-2025 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $77.28 | 2022-2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $76.82 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $73.50 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $67.29 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $55.87 | 2022 | |
| Sumitomo Pharma America, INC. | $43.23 | 2023-2024 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $33.57 | 2022 | |
| Dexcom, INC. | $14.70 | 2024 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $14.66 | 2023 | Xofluza |
| Xeris Pharmaceuticals, INC. | $14.56 | 2024 | Gvoke Hypopen |
| Eisai INC. | $12.92 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyssa Beall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.